Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mesutoclax
- Development stage
- Phase 3
- Lead developer
- InnoCare Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mesutoclax (ABBV-167) is an investigational, potent, and selective small molecule inhibitor of B-cell lymphoma 2 (BCL-2), an anti-apoptotic protein frequently overexpressed in various hematologic malignancies. Developed by AbbVie, mesutoclax is designed to induce apoptosis in cancer cells by selectively binding to the BH3-binding groove of BCL-2, thereby preventing it from sequestering pro-apoptotic proteins such as BIM and BAX. This mechanism effectively lowers the threshold for programmed cell death in malignant cells. Mesutoclax is currently being evaluated in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML), multiple myeloma (MM), and myelodysplastic syndromes (MDS). While it shares a similar mechanism of action with the first-in-class BCL-2 inhibitor venetoclax, mesutoclax is a chemically distinct entity being explored for its specific pharmacokinetic profile and potential efficacy in combination regimens.
- Other names
- ICP-248ICP248ICP 248mesutoclax
02
Targets
BCL-2 (BCL-2 family)
Beyond the preview
Go deeper on mesutoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mesutoclax.